- Conditions
- HIV-1-infection
- Interventions
- Bictegravir/Emtricitabine/Tenofovir Alafenamide 50 MG-200 MG-25 MG Oral Tablet [BIKTARVY]
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 40
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HIV-1 Infection
- Interventions
- BIC, F/TAF, DTG, BIC Placebo, DTG Placebo, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 15 more
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, BIC/LEN FDC, Stable Baseline Regimen
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 689 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 40
- States / cities
- Berkeley, California • Beverly Hills, California • Los Angeles, California + 34 more
- Conditions
- HIV Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to FDC DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 643 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 24 more
- Conditions
- Malignant Pleural Mesothelioma
- Interventions
- NGR-hTNF plus Best Investigator's Choice (BIC), Placebo plus Best Investigator's Choice (BIC)
- Drug
- Lead sponsor
- AGC Biologics S.p.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 7
- States / cities
- Corona, California • Duarte, California • Tampa, Florida + 4 more
- Conditions
- Healthy
- Interventions
- Bictegravir/emtricitabine/tenofovir alafenamide, Dolutegravir, MK4646
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Anniston, Alabama
- Conditions
- Suicide Prevention
- Interventions
- VA BIC, Standard Care
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- White River Junction, Vermont
- Conditions
- ART, HIV
- Interventions
- Biktarvy
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 49 Years · Male only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Epilepsy
- Interventions
- Brain Interchange System
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 3 Years to 70 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Houston, Texas
- Conditions
- Hiv, HIV-1-infection, HIV Infections
- Interventions
- DTG/3TC versus BIC/F/TAF
- Drug
- Lead sponsor
- Midway Specialty Care Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- West Palm Beach, Florida
- Conditions
- HIV/AIDS
- Interventions
- bictegravir/emtricitabine/tenofovir alafenamide (BIC/F/TAF), Standard initiation of antiretroviral therapy (ART)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska
- Conditions
- HIV-1 Infection
- Interventions
- elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy
- Drug
- Lead sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • San Diego, California • Torrance, California + 17 more
- Conditions
- HIV-1-infection
- Interventions
- Oral Lenacapavir, F/TAF, Subcutaneous Lenacapavir, TAF, BIC, B/F/TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Los Angeles, California • Palm Springs, California + 40 more
- Conditions
- Suicide Prevention
- Interventions
- PEACE, Standard Psychiatric Hospital Discharge Care
- Behavioral · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- White River Junction, Vermont
- Conditions
- HIV-1-infection
- Interventions
- Bictegravir, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 51
- States / cities
- Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
- Conditions
- Suicidal Ideation
- Interventions
- Dynamic Deconstructive Psychotherapy (DDP), Brief Intervention and Contact (BIC)
- Behavioral
- Lead sponsor
- State University of New York - Upstate Medical University
- Other
- Eligibility
- 14 Years to 40 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Syracuse, New York
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 19 more
- Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Interventions
- ISL, ULO, BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 11
- States / cities
- San Francisco, California • West Hollywood, California • Washington D.C., District of Columbia + 8 more
- Conditions
- HIV-1 Infection
- Interventions
- Islatravir, Ulonivirine, BIC/FTC/TAF, Placebo to ISL, Placebo to Ulonivirine, Placebo to BIC/FTC/TAF
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 10
- States / cities
- Phoenix, Arizona • Los Angeles, California • Ft. Pierce, Florida + 7 more
- Conditions
- HIV, Tuberculosis
- Interventions
- Bictegravir (BIC), Tenofovir alafenamide (TAF), Long-acting injectable formulation of cabotegravir (CAB LA), Dolutegravir (DTG), Atazanavir/ritonavir (ATV/r), Darunavir/ritonavir (DRV/r), Lopinavir/ritonavir (LPV/r), Cobicistat, Ritonavir, First-Line TB Treatment, Second-Line TB Treatment, Doravirine (DOR)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
- Conditions
- Body Weight Changes, Human Immunodeficiency Virus, ART, Obesity, Minority Health, BMD, Metabolic Syndrome, Fasting
- Interventions
- DOR/3TC/TDF, DOR + FTC/TAF, BIC/FTC/TAF
- Drug · Combination Product
- Lead sponsor
- Prism Health North Texas
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- HIV-1-infection
- Interventions
- Lenacapavir, Bictegravir/Lenacapavir (BIC/LEN) FDC, Bictegravir/Lenacapavir
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Tampa, Florida • Atlanta, Georgia + 1 more
- Conditions
- Advanced Breast Cancer, Stage 4 Breast Cancer, Recurrent Breast Cancer
- Interventions
- T-PAT, Surveys
- Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV-1 Infection
- Interventions
- DOR/ISL, BIC/FTC/TAF, Placebo to BIC/FTC/TAF, Placebo to DOR/ISL
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 14 more